Assessing the Risk Factors of Detectable Viral Loads after Switching to Dolutegravir and Lamivudine or Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate in a Real-World Cohort of Treatment-Experienced Adults Living with HIV
Medicine and Pharmacology - Epidemiology and Infectious Diseases
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Alerts
Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.